Expression Status of PIWIL1 as a Prognostic Marker of Colorectal Cancer

Table 2

Univariate survival analysis of OS and DFS in 110 patients with colorectal cancer.

Characteristics	DFS			OS
	Mean ± SE (months)	95% CI	^a	Mean ± SE (months)	95% CI	^a
Age (years)			0.421			0.332
<60	43.79 ± 2.57	38.75–48.84		44.50 ± 2.50	39.60–49.40
≥60	48.05 ± 2.20	43.74–52.36		49.50 ± 2.07	45.45–53.55
Sex			0.931			0.808
Male	45.01 ± 2.52	40.07–49.94		45.91 ± 2.43	41.14–50.68
Female	46.71 ± 2.32	42.17–51.25		47.94 ± 2.21	43.60–52.27
Tumor size			0.597			0.495
<5 cm	46.93 ± 2.64	41.76–52.09		47.76 ± 2.56	42.75–52.77
≥5 cm	45.12 ± 2.25	40.71–49.53		46.34 ± 2.16	42.11–50.56
TNM stage			<0.001			<0.001
I	55.49 ± 2.66	50.27–60.71		55.77 ± 2.58	50.71–60.82
II	54.44 ± 1.73	51.06–57.83		54.99 ± 1.62	51.81–58.16
III	33.52 ± 2.42	28.77–38.27		35.82 ± 2.43	31.06–40.59
IV	27.43 ± 6.19	15.29–39.56		28.19 ± 6.04	16.36–40.02
Differentiation			<0.001			<0.001
Well	54.44 ± 2.17	50.19–58.69		55.13 ± 2.00	51.20–59.05
Moderate	49.47 ± 2.03	45.49–53.46		50.83 ± 1.88	47.14–54.51
Poor	31.15 ± 3.32	24.65–37.65		32.12 ± 3.22	25.81–38.43
Infiltrate depth			<0.001			<0.001
T1 + T2	53.80 ± 2.19	49.50–58.10		53.99 ± 2.13	49.81–58.17
T3 + T4	40.74 ± 2.23	36.37–45.10		42.36 ± 2.16	38.12–46.60
Lymphovascular invasion			<0.001			<0.001
No	57.04 ± 1.30	54.49–59.60		57.19 ± 1.25	54.73–59.65
Yes	31.90 ± 2.25	27.50–36.30		34.10 ± 2.29	29.61–38.60
LNM			<0.001			<0.001
No	52.19 ± 1.74	48.79–55.59		53.02 ± 1.65	49.78–56.26
Yes	34.28 ± 2.85	28.69–39.87		35.78 ± 2.77	30.35–41.22
Tumor location			0.090			0.067
Rectum	43.48 ± 2.35	38.87–48.09		44.86 ± 2.25	40.45–49.27
Colon	48.48 ± 2.46	43.66–53.29		49.19 ± 2.39	44.51–53.87
PIWIL1 expression			0.002			0.003
Low	52.90 ± 1.83	49.31–56.50		53.53 ± 1.72	50.16–56.90
High	40.77 ± 2.45	35.97–45.57		42.14 ± 2.38	37.48–46.81

OS: overall survival; DFS: disease-free survival; SE: standard error; CI: confidence interval; LNM: lymph node metastasis; TNM: tumor node metastasis; ^alog-rank test.